{
    "medicine_id": "452f8dac4bf8b576de2dc63d88fec9e9fcaf11e7",
    "platform_id": "DB06069",
    "metadata": {
        "name": "Lartruvo 10 mg 1mL Injection solution",
        "composition": "10 mg 1mL XMT 1001",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in solid tumors",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In preclinical studies XMT 1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer showing extended plasma half life and high concentrations in tumor tissue The Phase I results show that in humans camptothecin the active agent in XMT 1001 is released gradually from the Fleximer carrier as a pro drug in a manner that will potentially avoid common safety problems associated with drugs in this class",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}